title: Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification?
abstract: Type 2 diabetes mellitus (T2DM) remains a leading cause of cardiovascular (CV) events and diseases worldwide. The aim of the review is to summarize our knowledge regarding clinical implementation of the biomarker-based strategy of the CV risk assessment in T2DM patient population. There is large body of evidence regarding use of the cardiac biomarkers to risk stratification at higher CV risk individuals who belongs to general population and cohort with established CV disease. Although T2DM patients have higher incidence of macrovascular and microvascular CV complications than the general population, whether cardiac biomarkers would be effective to risk stratification of the T2DM is not fully understood. The role of natriuretic peptides, galectin-3, interleukins, growth differentiation factor-15, as well as biomarkers of endothelial dysfunction are widely discussed. In conclusion, future directions, which associate with discovering of novel biomarkers and their best combinations to provide additional predictive information beyond other traditional CV risk factors, are discussed.
authors.affiliation: Private Hospital "Vita-Center", Zaporozhye, Ukraine; Internal Medicine Department, Medical University of Zaporozhye, Ukraine. Electronic address: dr_berezin@mail.ru.
authors.forename: Alexander E
authors.initials: AE
authors.lastname: Berezin
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D012307:Risk Factors
chemical_list: D015415:Biomarkers
keywords: Biomarkers; Cardiovascular disease; Diabetes mellitus; Mortality; Prediction; Risk